Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Imiquimod Tested as Nonsurgical Option
WASHINGTON - Imiquimod 5 percent cream (Aldara) continues to demonstrate promise as an effective and well tolerated topical therapy for the treatment of primary, superficial basal cell carcinoma, according to results from foreign and domestic Phase II dose-response studies presented at the annual meeting of the American Academy of Dermatology.
Related Videos
Related Content
